157 related articles for article (PubMed ID: 24824848)
1. Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma.
Malz M; Bovet M; Samarin J; Rabenhorst U; Sticht C; Bissinger M; Roessler S; Bermejo JL; Renner M; Calvisi DF; Singer S; Ganzinger M; Weber A; Gretz N; Zörnig M; Schirmacher P; Breuhahn K
Hepatology; 2014 Oct; 60(4):1241-50. PubMed ID: 24824848
[TBL] [Abstract][Full Text] [Related]
2. Concomitant expression of far upstream element (FUSE) binding protein (FBP) interacting repressor (FIR) and its splice variants induce migration and invasion of non-small cell lung cancer (NSCLC) cells.
Müller B; Bovet M; Yin Y; Stichel D; Malz M; González-Vallinas M; Middleton A; Ehemann V; Schmitt J; Muley T; Meister M; Herpel E; Singer S; Warth A; Schirmacher P; Drasdo D; Matthäus F; Breuhahn K
J Pathol; 2015 Nov; 237(3):390-401. PubMed ID: 26177862
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells.
Malz M; Weber A; Singer S; Riehmer V; Bissinger M; Riener MO; Longerich T; Soll C; Vogel A; Angel P; Schirmacher P; Breuhahn K
Hepatology; 2009 Oct; 50(4):1130-9. PubMed ID: 19585652
[TBL] [Abstract][Full Text] [Related]
4. Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.
Rahmutulla B; Matsushita K; Satoh M; Seimiya M; Tsuchida S; Kubo S; Shimada H; Ohtsuka M; Miyazaki M; Nomura F
Oncotarget; 2014 May; 5(9):2404-17. PubMed ID: 24811221
[TBL] [Abstract][Full Text] [Related]
5. Nuclear expression of the ubiquitin ligase seven in absentia homolog (SIAH)-1 induces proliferation and migration of liver cancer cells.
Brauckhoff A; Malz M; Tschaharganeh D; Malek N; Weber A; Riener MO; Soll C; Samarin J; Bissinger M; Schmidt J; Longerich T; Ehemann V; Schirmacher P; Breuhahn K
J Hepatol; 2011 Nov; 55(5):1049-57. PubMed ID: 21356256
[TBL] [Abstract][Full Text] [Related]
6. Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR.
Hsiao HH; Nath A; Lin CY; Folta-Stogniew EJ; Rhoades E; Braddock DT
Biochemistry; 2010 Jun; 49(22):4620-34. PubMed ID: 20420426
[TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.
Samarin J; Laketa V; Malz M; Roessler S; Stein I; Horwitz E; Singer S; Dimou E; Cigliano A; Bissinger M; Falk CS; Chen X; Dooley S; Pikarsky E; Calvisi DF; Schultz C; Schirmacher P; Breuhahn K
Hepatology; 2016 Mar; 63(3):813-26. PubMed ID: 26901106
[TBL] [Abstract][Full Text] [Related]
8. Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.
Matsushita K; Shimada H; Ueda Y; Inoue M; Hasegawa M; Tomonaga T; Matsubara H; Nomura F
World J Gastroenterol; 2014 Apr; 20(15):4316-28. PubMed ID: 24764668
[TBL] [Abstract][Full Text] [Related]
9. SAP155-mediated c-myc suppressor far-upstream element-binding protein-interacting repressor splicing variants are activated in colon cancer tissues.
Kajiwara T; Matsushita K; Itoga S; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Habara Y; Matsuo M; Nomura F
Cancer Sci; 2013 Feb; 104(2):149-56. PubMed ID: 23113893
[TBL] [Abstract][Full Text] [Related]
10. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
[TBL] [Abstract][Full Text] [Related]
11. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.
Matsushita K; Kitamura K; Rahmutulla B; Tanaka N; Ishige T; Satoh M; Hoshino T; Miyagi S; Mori T; Itoga S; Shimada H; Tomonaga T; Kito M; Nakajima-Takagi Y; Kubo S; Nakaseko C; Hatano M; Miki T; Matsuo M; Fukuyo M; Kaneda A; Iwama A; Nomura F
Oncotarget; 2015 Mar; 6(7):5102-17. PubMed ID: 25671302
[TBL] [Abstract][Full Text] [Related]
12. Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.
Matsushita K; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Levens D; He L; Liu J; Yoshida M; Nomura F
Mol Cancer Res; 2013 Jul; 11(7):689-98. PubMed ID: 23594796
[TBL] [Abstract][Full Text] [Related]
13. [Alternative Splicing Detection as Biomarker Candidates for Cancer Diagnosis and Treatment with Establishment of Clinical Biobank in Chiba University].
Matsushita K; Itoga S; Nishimura M; Furuta K; Nomura F
Rinsho Byori; 2015 Mar; 63(3):347-60. PubMed ID: 26524858
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.
Kano M; Matsushita K; Rahmutulla B; Yamada S; Shimada H; Kubo S; Hiwasa T; Matsubara H; Nomura F
Gene Ther; 2016 Jan; 23(1):50-6. PubMed ID: 26241176
[TBL] [Abstract][Full Text] [Related]
15. The FBP interacting repressor targets TFIIH to inhibit activated transcription.
Liu J; He L; Collins I; Ge H; Libutti D; Li J; Egly JM; Levens D
Mol Cell; 2000 Feb; 5(2):331-41. PubMed ID: 10882074
[TBL] [Abstract][Full Text] [Related]
16. SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression.
Matsushita K; Kajiwara T; Tamura M; Satoh M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Yoshimoto R; Ito A; Kubo S; Natsume T; Levens D; Yoshida M; Nomura F
Mol Cancer Res; 2012 Jun; 10(6):787-99. PubMed ID: 22496461
[TBL] [Abstract][Full Text] [Related]
17. Argonaute2 promotes tumor metastasis by way of up-regulating focal adhesion kinase expression in hepatocellular carcinoma.
Cheng N; Li Y; Han ZG
Hepatology; 2013 May; 57(5):1906-18. PubMed ID: 23258480
[TBL] [Abstract][Full Text] [Related]
18. Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth.
Yang WL; Wei L; Huang WQ; Li R; Shen WY; Liu JY; Xu JM; Li B; Qin Y
Oncol Rep; 2014 May; 31(5):2328-34. PubMed ID: 24676454
[TBL] [Abstract][Full Text] [Related]
19. CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors.
Liu M; Chen L; Ma NF; Chow RK; Li Y; Song Y; Chan TH; Fang S; Yang X; Xi S; Jiang L; Li Y; Zeng TT; Li Y; Yuan YF; Guan XY
Hepatology; 2016 May; 63(5):1544-59. PubMed ID: 27100146
[TBL] [Abstract][Full Text] [Related]
20. Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition.
Chung KY; Cheng IK; Ching AK; Chu JH; Lai PB; Wong N
Hepatology; 2011 Jul; 54(1):307-18. PubMed ID: 21520196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
